The effect of blood transfusion on HbA1c is a clinically important consideration for anyone managing diabetes in the UK. HbA1c — glycated haemoglobin — is the standard long-term marker of blood glucose control, but its accuracy depends on normal red blood cell lifespan and turnover. When donor red cells are introduced via transfusion, they carry their own glycation history, which can distort the recipient's HbA1c result in an unpredictable direction. Understanding this interaction is essential for clinicians and patients alike to avoid misinterpretation of results and ensure safe, informed diabetes management.

How HbA1c Is Measured and What Affects Its Accuracy

HbA1c measures glycated haemoglobin to reflect average blood glucose over 8–12 weeks, but its accuracy is compromised by conditions altering red cell lifespan, including haemolytic anaemia, iron deficiency, chronic kidney disease, and recent blood transfusion.

HbA1c, or glycated haemoglobin, is a widely used marker for assessing long-term blood glucose control in people with diabetes. It is a minor glycated fraction of adult haemoglobin (HbA) — not the predominant form of haemoglobin — formed when glucose in the bloodstream irreversibly binds to haemoglobin. Because red blood cells (erythrocytes) have a lifespan of approximately 120 days, HbA1c reflects average blood glucose concentration over the preceding eight to twelve weeks, providing a retrospective window into glycaemic trends rather than a snapshot of current glucose levels.

However, HbA1c is not infallible. Several physiological and pathological factors can distort its accuracy, making interpretation challenging in certain clinical contexts. These include:

• Haemoglobin variants such as HbS (sickle cell trait) or HbC, which may interfere with some assay methods — the degree of interference is method-dependent (for example, HPLC versus immunoassay); local laboratory notes and NGSP guidance detail variant-specific effects

• Haemolytic anaemia, which shortens red cell lifespan and falsely lowers HbA1c

• Iron deficiency anaemia, which can falsely elevate HbA1c by prolonging red cell survival

• Chronic kidney disease, pregnancy, and liver disease, all of which alter red cell turnover

• Recent blood transfusion, which introduces donor red cells with a different glycation history

NICE guidance (NG28 for type 2 diabetes and NG17 for type 1 diabetes) acknowledges these limitations and recommends that clinicians interpret HbA1c results in the context of the individual patient's clinical picture. The 2011 WHO/UK consensus statement on the use of HbA1c in the diagnosis of diabetes explicitly states that HbA1c should not be used for diagnosis — and should be interpreted with great caution for monitoring — when conditions alter red cell survival, including recent transfusion, haemolysis, pregnancy, and chronic kidney disease. When HbA1c is deemed unreliable, alternative markers of glycaemic control should be considered. Understanding these confounding variables is essential before exploring how blood transfusions, in particular, can significantly distort HbA1c readings.

Why Blood Transfusions Can Alter HbA1c Results

Transfused donor red cells introduce a different glycation history into the recipient's circulation, producing an unpredictable and potentially significant distortion in HbA1c that can persist for up to three months.

A blood transfusion introduces donor red blood cells into the recipient's circulation. These transfused erythrocytes carry their own glycation history, which reflects the donor's blood glucose environment rather than the recipient's. As a result, the overall proportion of glycated haemoglobin measured in the recipient's blood after transfusion may no longer accurately represent the recipient's glycaemic control over the preceding weeks or months.

The direction and magnitude of this effect are unpredictable. In most cases, transfused donor cells — which have not been exposed to the recipient's glucose environment — dilute the recipient's own glycated red cells, producing a spuriously low HbA1c result. However, the effect can also be in the opposite direction depending on the donor's own HbA1c, storage conditions, and the proportion of the recipient's circulating red cell mass that is replaced. Because the outcome cannot be reliably predicted, HbA1c should generally be avoided for approximately three months following any blood transfusion, whether for diagnosis or monitoring purposes.

Several factors influence the degree of distortion:

• Volume of blood transfused — larger transfusions replace a greater proportion of the recipient's own red cells

• Number of transfusion episodes — repeated transfusions compound the effect

• Timing of the HbA1c test — the closer the test is to the transfusion, the more pronounced the distortion

• Baseline haematological status — patients with pre-existing anaemia may receive proportionally larger volumes relative to their circulating red cell mass

• Donor HbA1c — the glycation level of transfused cells varies between donors

The distortion is not permanent but can persist for up to three months, mirroring the normal lifespan of a red blood cell. This temporal relationship is critical for clinicians to appreciate when scheduling HbA1c testing in patients who have recently received a transfusion. As a practical step, recent transfusion should always be documented on blood test request forms so that the laboratory can flag the result as potentially unreliable.

Clinical Evidence on Transfusion-Related HbA1c Changes

Studies consistently show transfusions cause clinically significant HbA1c distortions of 0.5% to over 2.0% (5.5–22 mmol/mol), with NGSP and RCPath guidance advising against relying on HbA1c within three months of transfusion.

The clinical literature consistently demonstrates that blood transfusions cause a measurable and clinically significant distortion in HbA1c values. Studies have reported changes ranging from approximately 0.5% to over 2.0% (5.5 to 22 mmol/mol), depending on the volume administered, the donor's HbA1c, and the patient's baseline haematological parameters. Even a single unit of packed red blood cells has been shown to produce a detectable change in HbA1c in some individuals. It is important to note, however, that the direction of change is not universally predictable — whilst a spuriously low result is more commonly reported, a spuriously elevated result is also possible. The overall consensus, reflected in NGSP guidance and RCPath/ACB laboratory medicine recommendations, is that HbA1c results obtained within approximately three months of a blood transfusion should not be relied upon for clinical decision-making.

A particularly illustrative body of evidence comes from patients with haematological conditions — such as thalassaemia or sickle cell disease — who require regular transfusions. In these populations, HbA1c is well recognised as an unreliable marker of glycaemic control, and alternative monitoring strategies are routinely employed. Research in surgical and critical care settings has similarly demonstrated that perioperative transfusions can substantially distort postoperative HbA1c readings, potentially masking poor glycaemic control at a clinically important time.

Some studies have explored whether the storage age of transfused blood influences the degree of HbA1c distortion; this remains an area of ongoing investigation and no firm conclusions can currently be drawn. The overall clinical message is clear: HbA1c obtained within three months of transfusion is unreliable and should be supplemented or replaced by alternative measures of glycaemic control.

Implications for Diabetes Monitoring After a Transfusion

A spuriously altered HbA1c after transfusion can lead to incorrect clinical decisions; clinicians should avoid HbA1c for approximately three months post-transfusion and use alternative monitoring methods instead.

For patients living with diabetes — whether type 1 or type 2 — who require a blood transfusion, the implications for ongoing glycaemic monitoring are significant. A spuriously low or high HbA1c result following transfusion could lead clinicians to incorrectly conclude that blood glucose control is satisfactory or worse than it actually is, potentially delaying necessary adjustments to medication, insulin regimens, or lifestyle interventions. Clinicians should avoid relying on HbA1c for approximately three months after a transfusion and should use alternative markers and clinical glucose data during this period.

This is particularly relevant in the following clinical scenarios:

• Postoperative care, where patients may have received intraoperative or perioperative transfusions and require accurate glycaemic assessment during recovery

• Acute medical admissions involving haemorrhage, gastrointestinal bleeding, or trauma, where transfusion is common

• Patients with chronic anaemia requiring regular transfusion support alongside diabetes management

• Pregnancy in women with diabetes, where both anaemia and transfusion are more prevalent, glycaemic targets are tighter, and self-monitored blood glucose (SMBG) and continuous glucose monitoring (CGM) are the primary monitoring tools — as outlined in NICE NG3 (Diabetes in Pregnancy)

Clinicians should document any transfusion clearly in the patient's medical record and flag this when requesting or interpreting HbA1c results. NICE guidance on diabetes management (NG28 for type 2 and NG17 for type 1) emphasises the importance of individualised monitoring, and this principle extends to recognising when standard markers may be unreliable. Patients themselves should be informed that their HbA1c result may not be accurate following a transfusion and that additional or alternative testing may be required.

Patients or carers should seek urgent medical advice if there are symptoms of severe hyperglycaemia (such as excessive thirst, frequent urination, or vomiting), suspected diabetic ketoacidosis, or recurrent severe hypoglycaemia during any period when routine monitoring is uncertain.

Alternative Tests for Assessing Blood Glucose Control

Fructosamine, which reflects average glucose over 2–3 weeks via glycated serum proteins, is the most commonly used alternative to HbA1c when red cell lifespan is unreliable; CGM and SMBG provide real-time glucose data unaffected by haematological variables.

When HbA1c is known or suspected to be unreliable — including in the period following a blood transfusion — alternative markers of glycaemic control should be considered. These tests assess different aspects of glucose metabolism and are not subject to the same confounding effects of red cell lifespan or haemoglobin composition.

Fructosamine is one of the most commonly used alternatives. It measures glycated serum proteins, primarily albumin, and reflects average blood glucose over the preceding two to three weeks. Because it is independent of red cell turnover, it is unaffected by transfusion. However, fructosamine results are influenced by conditions that alter serum protein or albumin levels — including nephrotic syndrome, liver disease, thyroid disorders, paraproteinaemia, and acute illness — and its reference ranges are less standardised than those for HbA1c. Interpretation should take these limitations into account, ideally with input from the local laboratory or a diabetes specialist.

Glycated albumin is a more specific measure within the fructosamine category and is increasingly used in research and specialist settings, though it is not yet widely available in routine NHS practice. Availability should be confirmed with the local laboratory.

Continuous glucose monitoring (CGM) and self-monitored blood glucose (SMBG) provide real-time glucose data and are entirely unaffected by haematological variables. CGM in particular offers detailed insight into glucose variability, time in range, and hypoglycaemic episodes — metrics that HbA1c alone cannot capture. NICE NG17 sets out criteria for CGM access in adults with type 1 diabetes, and NICE NG28 includes criteria for CGM and flash glucose monitoring in adults with type 2 diabetes who use insulin. Local commissioning arrangements may affect availability, and patients should discuss eligibility with their diabetes team.

The choice of alternative test should be guided by clinical context, local laboratory availability, and the individual patient's circumstances, ideally in discussion with a diabetes specialist team.

Guidance for Clinicians and Patients in the UK

UK clinicians should document all transfusion episodes, avoid HbA1c for approximately three months post-transfusion, and apply NICE NG17, NG28, or NG3 guidance when selecting alternative monitoring approaches.

In the UK, awareness of the effect of blood transfusion on HbA1c is an important aspect of safe and accurate diabetes management. RCPath and ACB (Association for Clinical Biochemistry and Laboratory Medicine) laboratory medicine guidance recommends that clinicians consider haematological factors — including recent transfusion — when interpreting HbA1c results. Laboratories may flag results as potentially unreliable if relevant clinical information is provided on the request form, underscoring the importance of clear documentation. NICE NG17 and NG28 provide the overarching framework for individualised monitoring in type 1 and type 2 diabetes respectively.

For clinicians, the following practical steps are recommended:

• Record all transfusion episodes in the patient's medical record, including date and volume

• Avoid relying on HbA1c for glycaemic diagnosis or monitoring for approximately three months after a transfusion

• Consider fructosamine or CGM/SMBG as alternative monitoring tools in the interim period, noting the limitations of each

• Communicate clearly with the laboratory by noting recent transfusion on blood test request forms so results can be appropriately flagged

• Apply NICE NG17, NG28, and NG3 (for pregnancy) when selecting monitoring approaches and targets

• Refer to a diabetes specialist if glycaemic management is complex or if results are difficult to interpret

For patients, the key messages are straightforward. If you have diabetes and have recently had a blood transfusion, it is important to let your GP, diabetes nurse, or hospital team know before having an HbA1c blood test. Your result may not accurately reflect how well your blood sugar has been controlled, and your healthcare team may recommend a different type of test in the meantime.

Continue your usual blood glucose monitoring at home and report any concerns about high or low readings to your healthcare team promptly. If you experience symptoms of severe high blood sugar — such as excessive thirst, frequent urination, nausea, or vomiting — or symptoms of severe low blood sugar, seek urgent medical advice. Further information on HbA1c testing and diabetes monitoring is available on the NHS website. Open communication between patients and clinicians remains the cornerstone of safe diabetes management, particularly in the context of acute illness or haematological intervention.

Not sure if this is normal? Chat with one of our pharmacists →

Frequently Asked Questions